Literature DB >> 8061811

Effect of a new cholecystokinin antagonist (FK 480) on gene expression of cholecystokinin and secretin in rat intestine.

A Funakoshi1, K Miyasaka.   

Abstract

The effects of a new cholecystokinin (CCK) antagonist (FK 480; 0.1 mg/kg per day given by intragastric administration to rats for 3 days) on the expression of the CCK and secretin genes, plasma CCK immunoreactivity, and CCK content in the intestinal mucosa were examined. FK 480 increased the level of CCK mRNA in the intestine to 1.7 times the level in control rats, but did not affect the level of secretin mRNA. It did not increase plasma CCK immunoreactivity or CCK content in the intestinal mucosa. These results suggest that the ingested FK 480 directly increased CCK mRNA level in the intestine and produced a dissociation between the synthesis and release of CCK.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8061811     DOI: 10.1007/bf02358383

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  8 in total

1.  Cholecystokinin receptor antagonist loxiglumide: influence on bilio-pancreatic secretion and gastrointestinal hormones in man.

Authors:  W E Schmidt; W Creutzfeldt; M Höcker; A R Choudhury; R Nustede; A Schleser; R Nitsche; L C Rovati; A Schafmayer; U R Fölsch
Journal:  Digestion       Date:  1990       Impact factor: 3.216

2.  The secretin precursor gene. Structure of the coding region and expression in the brain.

Authors:  N Itoh; T Furuya; K Ozaki; M Ohta; T Kawasaki
Journal:  J Biol Chem       Date:  1991-07-05       Impact factor: 5.157

3.  Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.

Authors:  H Tomita; K Miyasaka; A Jimi; Y Mishima; A Funakoshi
Journal:  Pancreas       Date:  1994-09       Impact factor: 3.327

4.  High plasma cholecystokinin levels in patients with chronic pancreatitis having abdominal pain.

Authors:  A Funakoshi; I Nakano; H Shinozaki; K Tateishi; T Hamaoka; H Ibayashi
Journal:  Am J Gastroenterol       Date:  1986-12       Impact factor: 10.864

5.  Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.

Authors:  H Ito; H Sogabe; T Nakarai; Y Sato; M Tomoi; M Kadowaki; M Matsuo; K Tokoro; K Yoshida
Journal:  J Pharmacol Exp Ther       Date:  1994-02       Impact factor: 4.030

6.  Effect of partial exclusion of pancreatic juice on rat basal pancreatic secretion.

Authors:  K Miyasaka; G M Green
Journal:  Gastroenterology       Date:  1984-01       Impact factor: 22.682

7.  Changes in plasma and duodenal cholecystokinin concentrations after pancreatic duct occlusion in rats.

Authors:  K Miyasaka; A Funakoshi; A Jimi; R Nakamura; M Matsumoto; K Kitani
Journal:  Dig Dis Sci       Date:  1992-03       Impact factor: 3.199

8.  Expression of the cholecystokinin precursor gene in rat tissues.

Authors:  A Funakoshi; A Tanaka; T Kawanami; K Tateishi; K Miyasaka; A Kono
Journal:  J Gastroenterol       Date:  1994-04       Impact factor: 7.527

  8 in total
  1 in total

1.  Effects of intraduodenal administration of a low dose of cholecystokinin (CCK) antagonist (CR-1505) on plasma CCK concentration, intestinal CCK content, and levels of CCK mRNA.

Authors:  N Sazaki; K Miyasaka; M Matsumoto; A Funakoshi
Journal:  J Gastroenterol       Date:  1995-10       Impact factor: 7.527

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.